ERP Clinical Trials

321 recruitingLast updated: July 25, 2026

There are 321 actively recruiting erp clinical trials across 60 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4. Top locations include Beijing, Beijing Municipality, China, Houston, Texas, United States, Beijing, China. Updated daily from ClinicalTrials.gov.


ERP Trials at a Glance

321 actively recruiting trials for erp are listed on ClinicalTrialsFinder across 6 cities in 60 countries. The largest study group is Not Applicable with 132 trials, with the heaviest enrollment activity in Beijing, Houston, and Beijing. Lead sponsors running erp studies include Beijing Tiantan Hospital, National Cancer Institute (NCI), and Beni-Suef University.

Browse erp trials by phase

Treatments under study

About ERP Clinical Trials

Looking for clinical trials for ERP? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ERP trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ERP clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 321 trials

Recruiting
Phase 2Phase 3

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.153 enrolled43 locationsNCT07159841
Recruiting
Phase 3

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.150 enrolled55 locationsNCT07144163
Recruiting

Natural History Study of Patients With Excess Androgen

Congenital Adrenal Hyperplasia (CAH)Familial Male-Limited Precocious Puberty (FMPP)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)3,000 enrolled2 locationsNCT00250159
Recruiting
Phase 2

Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

Prostatic HyperplasiaUrinary Urge IncontinenceStress Urinary Incontinence
National Cancer Institute (NCI)41 enrolled1 locationNCT06161506
Recruiting
Phase 3

Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL

Hospital-Acquired PneumoniaCommunity-acquired PneumoniaVentilator associated pneumonia+2 more
Jena University Hospital616 enrolled28 locationsNCT06134492
Recruiting
Phase 2

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

End Stage Renal Disease on DialysisHyperphosphatemiaChronic Kidney Disease Requiring Chronic Dialysis
R1 Therapeutics168 enrolled31 locationsNCT06712654
Recruiting

Viral Infections in Healthy and Immunocompromised Hosts

Herpes LabialisCOVID-19Anogenital Herpes
National Institute of Allergy and Infectious Diseases (NIAID)1,000 enrolled1 locationNCT01306084
Recruiting
Phase 2

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast CarcinomaEstrogen Receptor-Positive Breast CarcinomaBreast Ductal Carcinoma in Situ+3 more
National Cancer Institute (NCI)200 enrolled11 locationsNCT06184750
Recruiting

MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base Morphology

Prostate CancerBenign Prostatic HyperplasiaUrethral Internal Sphincter Morphology
Jiangsu Taizhou People's Hospital80 enrolled1 locationNCT07694752
Recruiting
Not Applicable

Serpentine vs Traditional Hydrophilic Guidewire Tracking in Complex Radial Anatomy

Vascular complicationsPercutaneous Coronary Intervention (PCI)Coronary Catheterization+7 more
University Hospital of Patras204 enrolled1 locationNCT07707427
Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Heart FailurePainInsomnia+22 more
Duke University5,000 enrolled51 locationsNCT04278404
Recruiting
Phase 3

Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia

Neuropathic PainDiabetic NeuropathyNeuralgia, Postherpetic
Brainfarma Industria Química e Farmacêutica S/A348 enrolled15 locationsNCT07712913
Recruiting

The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons

Ovarian CancerEndometrial CancerEndometrial Cancer Precursors+1 more
University of Alabama at Birmingham1,500 enrolled1 locationNCT03538665
Recruiting
Phase 1Phase 2

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

Herpes Zoster
National Institute of Allergy and Infectious Diseases (NIAID)225 enrolled1 locationNCT05580458
Recruiting
Not Applicable

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Prostate CancerProstatectomyBenign Prostatic Hyperplasia+3 more
Axonics, Inc.150 enrolled21 locationsNCT06511141
Recruiting
Not Applicable

Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

Benign Prostatic Hyperplasia
Urotronic Inc.92 enrolled7 locationsNCT06312722
Recruiting
Phase 2

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast CarcinomaBreast Ductal Carcinoma in SituBreast Atypical Hyperplasia+1 more
National Cancer Institute (NCI)80 enrolled4 locationsNCT05941520
Recruiting

Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer

Prostate Cancer (Adenocarcinoma)Localized Prostate CarcinomaProstate Hyperplasia+1 more
University of Zurich75 enrolled3 locationsNCT06834152
Recruiting
Phase 3

Subcutaneous Calcitonin in Acute Herpes Zoster

CalcitoninAcute Herpes ZosterSubcutaneous
Tanta University168 enrolled1 locationNCT07655804
Recruiting
Phase 2

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

Endometrial Endometrioid AdenocarcinomaEndometrial Hyperplasia
New Mexico Cancer Research Alliance140 enrolled4 locationsNCT07436793